Swedish Orphan Biovitrum AB

Sobi Completes Class C Share Transactions to Fulfill Incentive Obligations

Swedish Orphan Biovitrum AB (Sobi) has completed the issuance and repurchase of class C shares, a strategic financial move that underscores its commitment to fulfilling incentive obligations and reinforces its financial stability and reputation in t…

Swedish Orphan Biovitrum AB
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

21/08/2025, 13:04

2 minutes to read

SOBI Authorizes Share Repurchase, Signals Strong Financial Growth and Strategic Confidence

Swedish Orphan Biovitrum AB (SOBI) has authorized share repurchases and is expected to report strong financial growth, positioning the company for future success in the biotechnology sector.

Swedish Orphan Biovitrum AB
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

15/07/2025, 20:06

3 minutes to read

SOBI Reports 3% Revenue Increase in Q1 2025, Driven by Haematology Growth Amid Immunology Challenges

Swedish Orphan Biovitrum AB (SOBI) reported a 3% increase in Q1 2025 revenue to SEK 6,465 million, driven by growth in its haematology segment.

Swedish Orphan Biovitrum AB
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

29/04/2025, 14:33

2 minutes to read